AstraZeneca Signs Blockbuster Deal With Ionis for TTR Amyloidosis Treatment

AstraZeneca struck a deal worth up to more than $3.5 billion with Ionis Pharmaceuticals for the rights to develop and commercialize their transthyretin (TTR) amyloidosis treatment.